Phase 3 N=70 The Efficacy of Symbiotic on Cytokines
Necrotising Enterocolitis
Primary: Interleukin 5 Serum Cytokine Level on 0+2 Day — 4; 4 pg/ml — p=0.32
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Anakinra as a Treatment for Hydradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Change in Modified Sartorius Score — -34.8 units on a scale — p=0.024
N/A N=15 Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
Dry Mouth
Primary: Change From Baseline in Saliva Production in ml. — 1.41; 3.93; 5.31; 10.34 ml — p=0.05
Phase 3 N=341 American Ginseng in Treating Patients With Fatigue Caused by Cancer
Chronic Myeloproliferative Disorders · Fatigue · Leukemia
Primary: Change From Baseline to Week 4 in the General Subscale of the MFSI-SF — 14.4; 8.2 units on a scale — p=0.0737
Phase 3 N=934 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 65.0; 68.6; 73.2; 8.5 percentage of participants
Phase 3 N=204 Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
Schizophrenia, Paranoid · Schizophrenia, Disorganized · Schizophrenia, Undifferentiated
Primary: Number of Participants With a Treatment-Emergent Adverse Event (AE) During Extension Study — 114; 3 participants
Phase 4 N=38 Folate Supplementation in Schizophrenia
Schizophrenia
Primary: Correlation Between Baseline Blood Folate and Smoking Status — 14.6; 14.6; 14.2; 614 nanograms per milliliter
Phase 3 N=201 The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Diabetic Foot Ulcer of Neuropathic Origin
Primary: Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition — 14.1; 10.8…
Phase 2 N=10 Fulvestrant in Hormone Refractory Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: PSA Reduction ≥ 50% — 0 participants
Phase 3 N=360 Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects
Acne Vulgaris
Primary: Absolute Change in Total Lesion Counts From Baseline to Week 12 — -42.9; -22.0 Lesion counts — p=<0.001
Phase 3 N=538 Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
Insomnia · Sleep Initiation and Maintenance Disorders · Mental Disorders
Primary: Average Wake Time After Sleep Onset Measured by Polysomnography — 80.3; 79.6; 74.8; 109.8 Minutes — p=<0.0001
Phase 4 N=26 A Study of Sertraline to Prevent PTSD
Posttraumatic Stress Disorder · Depression
Primary: Diagnostic Interview Schedule for Children and Adolescents (DICA) - Parent — -0.2; -4.0 units on a scale — p==0.017
Phase 2 N=150 Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
Psoriasis
Primary: Number of Participants in Each Treatment Group With Clinical Cure: Physician's Global Assessment (PGA) Score = 0 or 1 at Day 28 — 13.33; 10.00; 20.69; 37.93 percentage…
N/A N=40 The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
HIV · Hepatitis C, Chronic · HCV Coinfection
Primary: Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients. — 5.8; 5.84; 5.84; 6.9 relative expression levels
Phase 2 N=153 Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Local Regional Control Rate at 2 Years — 0.61; 0.68 proportion of paticipants